You should be aware that these statements are projections or estimates as to future events and are subject to a number of factors that may tend to influence the accuracy of the statements. These forward-looking statement

CAUTIONARY NOTE REGARDING FORWARD-LOOKING

This Exhibit 99.1 contains forward-looking

statements that have been made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 and concern matters

that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking

statements. In some cases, you can identify these statements by terminology such as "may," "will," "should,"

"could," "expect," "plan," "anticipate," "believe," "estimate,"

"predict," "potential," "continue" or similar words which are intended to identify forward-looking

statements, although not all forward-looking statements contain these words. Although we believe that our opinions and expectations

reflected in the forward-looking statements are reasonable as of the date hereof, we cannot guarantee future results, levels of

activity, performance or achievements, and our actual results may differ substantially from the views and expectations set forth

in this Exhibit 99.1. You should be aware that these statements are projections or estimates as to future events and are subject

to a number of factors that may tend to influence the accuracy of the statements. These forward-looking statements should not be

regarded as a representation by us or any other person that our events or plans will be achieved. You should not unduly rely on

these forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation

to publicly revise any forward-looking statement to reflect circumstances or events after the date hereof or to reflect the occurrence

of unanticipated events. You should, however, review the factors and risks we describe in the reports we file from time to time

with the Securities and Exchange Commission and those reports filed after the date hereof. Actual results may differ materially

from any forward looking statement.

We are redefining the temperature-controlled

supply chain for the life sciences industry by providing a unique and evolving platform of critical products and solutions, including

advanced packaging, informatics, specialty logistics services, biostorage services, and cryogenic life sciences equipment. With

over 600 employees spread across 30 locations worldwide, we are engaged in providing global solutions to the pharma/biopharma,

reproductive medicine, and animal health markets. Our primary focus is on addressing the critical temperature-controlled supply

chain needs within the biopharmaceutical space with an emphasis on serving the rapidly-growing cell and gene therapy, or C&GT,

We are focused on establishing best-in-class,

comprehensive temperature-controlled supply chain solutions that support the expanding global landscape of the life sciences industry.

We believe our growth strategy aligns with the growth of the markets we serve and our customers within them. In particular, we

identified the C&GT market as a high growth market, with unmet supply chain needs that we believe can benefit significantly

from our solutions. The global C&GT market was valued at approximately $4.2 billion in 2019 and is projected to grow to over

$33.1 billion by 2024.

Over the last several years, we have grown

to become a leader in supporting C&GT clinical trials globally. As of the end of the third quarter of 2020, we supported over

500 clinical trials and four commercial therapies, including KYMRIAH by Novartis and YESCARTA by Gilead/Kite. In addition, seven

additional Cryoport supported therapies filed for commercial approval with the U.S. Food and Drug Administration, or FDA, or the

European Medicines Agency, or EMA, as of the end of the third quarter of 2020. Based on publicly disclosed information, industry

data, and internal forecasts, we estimate that up to 23 additional Cryoport supported C&GTs, currently in clinical trials,

may file for regulatory approval during the course of 2021. Commercial approvals of these therapies provide an opportunity to become

significant revenue drivers for us in the future as each of them requires comprehensive temperature-controlled supply chain support

and services at commercial scale, and we expect that many will select us as their critical supply chain solution as a result of

our work in connection with their clinical trials.

We intend to build on our recent history

of developing market-leading, temperature-controlled supply chain solutions and delivering strong growth through the following

We use our competencies and capabilities

to develop comprehensive and reliable, technology-centric solutions that address the specific needs of our customers. Our platform

of temperature-controlled supply chain products and solutions includes cold-chain and cryogenic life sciences equipment, advanced

packaging, informatics, specialty logistics services, biostorage services, kitting, labeling, and fulfillment. These products and

solutions are utilized for temperature-controlled supply chain services in the life sciences industry for personalized medicine,

cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals,

infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures

Our Cryoport Express Solutions are comprised

primarily of a sophisticated, cloud-based, logistics management platform, which is branded as the Cryoportal Logistics Management

Platform, or the Cryoportal, Cryoport Express Shippers and the SmartPak Condition Monitoring System, or the SmartPak. The Cryoportal

supports the management of shipments through a single interface, which includes order entry, document preparation, customs documentation,

courier management, near real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements.

In addition, it provides unique and incisive information dashboards and validation documentation for every shipment through data

collected by the SmartPak. The Cryoportal can record and retain a fully documented history of all Cryoport Express Shippers, including

chain-of-custody, chain-of-condition, chain-of-identity, and Chain of Compliance information for each shipment, which is

used to ensure that the stability of shipped biologic commodities are maintained throughout the shipping cycle.At the client's

option, recorded information is archived, allowing the client to meet exacting requirements necessary for scientific work and/or

proof of regulatory compliance during the logistics process.

During 2018 we introduced our Chain of Compliance

solution, as a new industry standard within the C&GT market. Our Chain of Compliance goes beyond chain of condition, chain

of custody and chain of identity by providing traceability of the equipment and processes supporting each client or

patient therapy. The Chain of Compliance enables us to recall any single or every transport that an individual Cryoport Express

Shipper has taken, the client(s) it supported, the commodity transported, its performance during transit, and each step that we

perform before the shipper is put back into service. This includes Cryoport Express Shipper performance and requalification history,

commodity history, courier handling and performance history, calibration history, and correlation competencies that can link in

field events to equipment performance. Many of these standards have now been incorporated in the recently released ISO-21973 standard

and we believe they are likely to become regulatory requirements in the near future.

In September of 2019, the Cryoport Express

Advanced Therapy Shippers were launched to address specific needs of biopharma companies developing and commercializing C&GTs.

These Advanced Therapy Shippers provide verification processes to ensure that they have only been used for human-based therapies

and materials and employ advanced validated cleaning methods to minimize the risk of cross-contamination of equipment and materials

during use, delivery, and distribution of biopharmaceutical materials.

We further extended our solutions, capabilities,

and global logistics network through the following recent acquisitions:

In May 2019, we expanded our capabilities

by acquiring Cryogene Partners, a Texas general partnership doing business as Cryogene Labs, or Cryogene. Cryogene operates an

expanding state-of-the-art temperature-controlled biostorage solutions business strategically located in Houston, Texas. Cryogene

is an industry leader in the management of pre-clinical services which include critical biological commodities to support clinical

research, the advancement of C&GTs, GMP biologics, and public health research. It provides customized, end-to-end chain of

custody/chain of condition solutions for its clients.

In October 2020, we further expanded our

capabilities by acquiring CRYOPDP, a leading global provider of innovative temperature-controlled logistics solutions for high

value, time critical and temperature-sensitive pharmaceuticals. CRYOPDP covers a significant portion of the healthcare temperature-controlled

supply chain including packaging, pick-pack kit preparation, premium services and specialty pharma/biopharma courier support. This

acquisition increased our global presence to a network of 27 global supply chain centers in 13 countries. This network gives us

a new advantage when serving global multinational customers and also provides redundancies and backup that reduce supply chain

risk for our customers. CRYOPDP has also developed a cloud-based platform branded as UnITy, which we plan to integrate with our

Cryoportal Logistics Management Platform. UnITy provides functionalities such as Transport Management System, Warehousing Management

System, Quality Management System, a Customer Experience portal, mobile apps for track and trace during transport and storage as

well as integration with transportation agents and business partners.

In October 2020, we made a second acquisition,

acquiring MVE Biological Solutions from Chart Industries, Inc. MVE Biological Solutions provides cryobiological storage and transportation

solutions for the life sciences industry through its advanced line of cryogenic stainless-steel freezers, aluminum dewars and related

ancillary equipment used in the storage and transport of life sciences commodities, which includes the rapidly growing C&GT

business. With three primary facilities, located in Ball Ground, Georgia, New Prague, Minnesota and Cheng-du, China, MVE Biological

Solutions is a leader in serving the life sciences industry throughout the world. The acquisition is a vertical integration that,

in addition to expanding our footprint to handle the growing demand driven by the growth in the C&GT market, helps to secure

our supply of cryogenic shippers and storage equipment. Cryobiological storage and transport clients include medical laboratories,